- Six Swiss institutional funds purchase existing shares of the Company in a secondary placement
Mont?Saint?Guibert, Belgium, ? Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the addition of six Swiss institutional funds to its shareholder base.
This transaction occurred aside of the market by exchange of shares between certain historical shareholders of the Company and Swiss professional investors. The transaction involved the sale of 141,800 shares at €43.5 each.The proportion of shares sold by the existing shareholders does not exceed 25% of their stake in the Company. The share capital and the number of shares of the Company remain unchanged after this secondary transaction.
Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: “We are delighted to welcome new institutional funds to our shareholders. It reinforces our institutional shareholders base and has allowed us to manage to the benefit of all our shareholders the partial exit of some historical shareholders of the Company,”